Last reviewed · How we verify
WX-0593 Tablets
WX-0593 Tablets is a small molecule drug that targets the HIF-1α pathway.
WX-0593 Tablets is a small molecule drug that targets the HIF-1α pathway. Used for Non-small cell lung cancer.
At a glance
| Generic name | WX-0593 Tablets |
|---|---|
| Also known as | FL-006, Iruplinalkib |
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Drug class | HIF-1α inhibitor |
| Target | HIF-1α |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
WX-0593 Tablets works by inhibiting the activity of HIF-1α, a protein that plays a key role in the body's response to low oxygen levels. This inhibition leads to a decrease in the production of vascular endothelial growth factor (VEGF), a protein involved in angiogenesis. By reducing VEGF levels, WX-0593 Tablets aims to inhibit tumor growth and metastasis.
Approved indications
- Non-small cell lung cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
- Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer (PHASE2)
- Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients (PHASE3)
- Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients (PHASE2)
- WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC (PHASE2)
- A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer (PHASE2)
- A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WX-0593 Tablets CI brief — competitive landscape report
- WX-0593 Tablets updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI